Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
:MLYS
Earnings Data
Report Date
Mar 18, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.51Last Year’s EPS
-0.98Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted several positive developments, including successful clinical trial outcomes and a strong financial position, with sufficient funds to support operations into 2028. The company is progressing well towards NDA submission. However, there were concerns regarding data imputation and increased G&A expenses. Overall, the positive aspects outweigh the challenges.Company Guidance
Successful Clinical Trial Outcomes
Lorundrostat demonstrated a clinically meaningful and sustained reduction in systolic blood pressure in both Launch-HTN and Advance-HTN pivotal trials, with consistent, statistically significant reductions across diverse patient populations, including subgroups like African-Americans and women.
Strong Financial Position
Mineralys ended the quarter with $593.6 million in cash, cash equivalents, and investments, sufficient to fund planned clinical trials and regulatory activities into 2028.
Reduction in Net Loss
Net loss decreased to $36.9 million for the quarter, compared to $56.3 million in the same quarter last year, primarily due to a decrease in R&D expenses.
Promising Exploratory Trials
The Explore-CKD trial showed a clinically meaningful reduction in systolic BP and was well tolerated, with 77% of surveyed healthcare professionals indicating they would consider prescribing lorundrostat to CKD patients with uncontrolled hypertension.
Preparation for NDA Submission
Mineralys received pre-NDA feedback from the FDA with no surprises and is moving ahead with its NDA filing for lorundrostat, expected either late in the current quarter or in the first quarter of 2026.
MLYS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MLYS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 10, 2025 | $44.50 | $47.11 | +5.87% |
Aug 12, 2025 | $13.51 | $13.56 | +0.37% |
May 12, 2025 | $15.01 | $15.19 | +1.20% |
Feb 12, 2025 | $9.66 | $10.63 | +10.04% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mineralys Therapeutics, Inc. (MLYS) report earnings?
Mineralys Therapeutics, Inc. (MLYS) is schdueled to report earning on Mar 18, 2026, After Close (Confirmed).
What is Mineralys Therapeutics, Inc. (MLYS) earnings time?
Mineralys Therapeutics, Inc. (MLYS) earnings time is at Mar 18, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MLYS EPS forecast?
MLYS EPS forecast for the fiscal quarter 2025 (Q4) is -0.51.